Sanofi and Cheplapharm announce mature medicines partnership
Sanofi plans to transfer 20 mature medicines and three manufacturing sites to Cheplapharm in exchange for a 26.4% equity stake in the German company.
SEC filing
Latest
35 stories
Tuesday, September 29
Thursday, September 24
Kaiser Permanente registers COVID vaccine choice messaging trial with Sanofi as collaborator
Tuesday, September 22
Sinovac registers two new not-yet-recruiting trials for PCV13 and Anflu
Thursday, September 17
Wednesday, September 16
Alkermes announces Anne C. Whitaker's appointment to board via press release
The company confirmed the September 14 board appointment in a September 16 statement that included executive comments and details on Whitaker's background.
SEC filing
Avalyn Pharma adds Robert Meyer, M.D. to board of directors
The former FDA official and regulatory consultant joins as a Class II director effective September 15, 2026.
SEC filing
Monday, September 14
INmune Bio adds two directors with rare-disease and business-development backgrounds
The company appointed R. Duane Clark II and James Sapirstein to its board on September 8, 2026, as Ebstrocel nears potential commercialization.
SEC filing
Friday, September 11
Korsana Biosciences completes Cyclerion merger, closes $380 million private placement
The combined company begins trading as KRSA on Nasdaq September 9, with cash expected to fund operations into 2029 as it advances its Alzheimer's antibody program.
SEC filing
Thursday, September 10
Sanofi registers Phase 2b hidradenitis suppurativa trial; RSV+HMPV vaccine study recruiting
Wednesday, September 2
Scribe Therapeutics starts Phase 1 trial of PCSK9 silencer STX-1150, completes upsized IPO
Cardiovascular gene-editing company reports first clinical data expected in H1 2027 and cash runway into H1 2029 after $155.5 million IPO and Sanofi private placement.
SEC filing
Monday, August 31
Sanofi's itepekimab COPD mechanism study AERIFY-3 posts results after 2025 completion
FDA approves labeling supplement for Children's Xyzal Allergy 24HR oral solution
Friday, August 28
Sanofi registers Phase 3 extension study for lunsekimig in COPD, named COLOSSUS
Sinovac recruits Phase III hepatitis A study; registers EV71 bridging trial in Vietnam
Friday, August 21
Sanofi advances belumosudil Phase 3 in cGVHD; H5N8 flu vaccine study recruiting
Friday, August 14
Innate Pharma to hold conference call August 14, 2026
The company announced a call and webcast on August 14, 2026 featuring its CEO, COO, CFO, and IR head.
SEC filing
Wednesday, August 12
Madrigal adds J&J R&D executive John C. Reed to board of directors
The company grew its board to nine seats and named Reed, who oversees Johnson & Johnson's innovative medicine research and development, to a Class II director term.
SEC filing
Tuesday, August 11
Yale registers Gaucher natural history study with Sanofi collaboration
Monday, August 10
Agomab proposes Marino Garcia and Dr. Naimish Patel for board seats
Belgium-based Agomab Therapeutics plans to add the two as non-executive directors, pending a shareholder vote in September 2026.
SEC filing
Thursday, August 6
Sanofi wins EU approval for MenQuadfi in infants from six weeks old
The European Commission extended MenQuadfi's indication to cover infants as young as six weeks against invasive meningococcal disease, expanding on the prior 12-months-and-older approval.
SEC filing
Novavax raises 2026 revenue outlook, flags Sanofi trial talks and C. diff progress
Novavax lifted its full-year revenue framework to $235-$275 million and said Sanofi is in advanced regulatory talks over its combination COVID-flu trial timing.
SEC filing
Sanofi posts results across four trials; RSV toddler study OPAL ended early by sponsor decision
Wednesday, August 5
Vir reports Week 96 SOLSTICE data, ECLIPSE program fully enrolled, VIR-5500 expansion underway
Second-quarter update details 88% viral suppression in hepatitis delta trial, Astellas collaboration progress, and $1.0 billion cash position.
SEC filing
Kymera moves up KT-621 atopic dermatitis data after fast enrollment
Faster-than-planned enrollment in the STAT6 degrader's Phase 2b trial pulls the readout forward to year-end 2026 and sets up an earlier Phase 3 start.
SEC filing
Thursday, July 30
Results post for old USC gastric cancer trial; Bristol Myers Squibb opens new Zeposia PML study
Sanofi registers alirocumab cardiovascular outcomes study; RSV+HMPV vaccine trial recruiting
Regeneron reports Q2 2026 results, cemdisiran filings accepted, fianlimab trial misses
Regeneron's second-quarter release recaps June 2026 FDA and EMA acceptance of cemdisiran filings for generalized myasthenia gravis and a Phase 3 fianlimab trial that missed its primary endpoint.
SEC filing
Wednesday, July 29
Teva posts Q2 2026 GAAP loss on Emalex charge, raises innovative brand outlook
Teva reported a $576 million net loss tied to the Emalex acquisition and ecopipam NDA filing, while raising its 2026 revenue outlook for AUSTEDO, AJOVY and UZEDY.
SEC filing
Friday, July 24
Sanofi's week: AVAPRO label update, new belumosudil BE study, two TB trial results posted
Scribe Therapeutics prices $128.7 million IPO at $15 per share
The clinical-stage CRISPR company will sell 8,580,000 shares on Nasdaq under "SCTX," with a Sanofi affiliate committing to a concurrent private placement.
SEC filing
Thursday, July 23
Innate Pharma to join bladder cancer panel at BTIG conference
The company's chief medical officer will speak on changing treatments in bladder cancer at the BTIG Virtual Biotechnology Conference on July 28, 2026.
SEC filing
Friday, July 17
Sanofi posts rilzabrutinib atopic dermatitis results; opens Phase 3 meningococcal vaccine trial in C
Regeneron registers Phase 3 PICC clot-prevention trial; Sanofi runs sarilumab study as collaborator
Wednesday, July 15
FDA approves subcutaneous Sarclisa Escena with on-body injector for multiple myeloma
Monday, July 13
Lakefront board member Fontoura resigns after Sanofi names him R&D chief
Paulo Fontoura steps down from Lakefront Biotherapeutics' board following his appointment to a top research role at Sanofi.
SEC filing